Straight Path Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-16,200
| Closed | -$14.7K | – | 98 |
|
|
2024
Q3 | $14.7K | Hold |
16,200
| – | – | 0.01% | 98 |
|
|
2024
Q2 | $16.2K | Hold |
16,200
| – | – | 0.01% | 96 |
|
|
2024
Q1 | $24K | Hold |
16,200
| – | – | 0.01% | 90 |
|
|
2023
Q4 | $17.7K | Hold |
16,200
| – | – | 0.01% | 90 |
|
|
2023
Q3 | $19.1K | Hold |
16,200
| – | – | 0.01% | 80 |
|
|
2023
Q2 | $22.8K | Hold |
16,200
| – | – | 0.02% | 77 |
|
|
2023
Q1 | $24.3K | Hold |
16,200
| – | – | 0.02% | 73 |
|
|
2022
Q4 | $19K | Hold |
16,200
| – | – | 0.02% | 71 |
|
|
2022
Q3 | $18K | Hold |
16,200
| – | – | 0.02% | 73 |
|
|
2022
Q2 | $26K | Hold |
16,200
| – | – | 0.03% | 72 |
|
|
2022
Q1 | $25K | Hold |
16,200
| – | – | 0.02% | 69 |
|
|
2021
Q4 | $40K | Buy |
+16,200
| New | +$40K | 0.03% | 77 |
|